Charlevoix‑Saguenay spastic ataxia is a rare genetic condition that affects balance, coordination, and muscle control. It usually starts in childhood or the teen years and tends to progress slowly over time. People with Charlevoix‑Saguenay spastic ataxia often have unsteady walking, stiff or tight leg muscles, and slurred speech, and doctors may also see reflex changes and eye movement problems. Many living with Charlevoix‑Saguenay spastic ataxia benefit from physical, occupational, and speech therapy, and some take medicines to ease muscle stiffness and manage symptoms. Life span is often near normal, but daily function can be affected, so regular follow‑up and supportive care are important.
Overview
Charlevoix-saguenay spastic ataxiaSymptoms
Early symptoms of Charlevoix-Saguenay spastic ataxia include balance and coordination problems, frequent falls, and slurred speech. Legs often feel stiff and tight, with worsening walking and hand clumsiness. Some develop numbness or weakness in feet and hands, vision shake, fatigue.
Outlook and prognosis
Most people with Charlevoix‑Saguenay spastic ataxia notice slow changes over years, not weeks. With coordinated care—physiotherapy, mobility aids, speech and swallowing support—many maintain independence in daily routines and plan work and family life. Life expectancy is often near typical.
Causes and risk factors
Charlevoix‑Saguenay spastic ataxia stems from inherited changes in the SACS gene; it’s autosomal recessive, usually present from early life. Risk rises when both parents are carriers, especially in certain founder populations; lifestyle factors don’t cause it but may influence complications.
Genetic influences
Genetics is central in Charlevoix-Saguenay spastic ataxia; it’s an inherited condition caused by variants in a single gene. Most cases follow an autosomal recessive pattern, meaning two altered copies are needed. Family history and carrier status strongly influence risk.
Diagnosis
Diagnosis relies on clinical features and is confirmed with genetic tests. Brain MRI and eye exam findings often support the genetic diagnosis of Charlevoix‑Saguenay spastic ataxia.
Treatment and drugs
Treatment for Charlevoix‑Saguenay spastic ataxia focuses on easing stiffness, improving balance, and supporting daily function. Care often includes physiotherapy, occupational therapy, speech therapy, muscle‑relaxing medicines, and mobility aids. Regular follow‑up helps tailor supports as needs change.
Symptoms
Walking may feel stiff and unsteady, and small hand tasks can take more effort. You might notice small changes at first, like tripping on uneven ground or taking longer to button a shirt. Early features of Charlevoix-saguenay spastic ataxia often include balance trouble, a tight-legged walk, and clumsy hand movements. These signs usually begin in childhood or the teen years and tend to persist over time.
In medical terms, this is ataxia; in everyday life, it shows up as unsteady steps, veering to one side, or trouble with quick turns. People may feel clumsy on stairs or when walking in the dark.
In Charlevoix-saguenay spastic ataxia, tight leg muscles can make the knees pull in and the legs cross while walking. This stiff pattern can cause toe-first steps and make uneven ground or stairs harder.
Speech can sound slurred or slow, especially when tired. Longer sentences may be harder to say clearly.
Tasks like writing, using keys, or fastening buttons can take longer and require more focus. Hands may feel shaky or less precise.
How people usually first notice Charlevoix-saguenay spastic ataxia?
Many families first notice Charlevoix‑Saguenay spastic ataxia in early childhood when a child seems unusually unsteady, falls often, or has a stiff, scissoring walk that doesn’t match peers’ motor milestones. Doctors may first recognize it during check-ups by seeing a mix of poor balance and coordination (ataxia), increased muscle tightness and reflexes in the legs (spasticity), and sometimes eye movement problems or slurred speech developing over time. These “first signs of Charlevoix‑Saguenay spastic ataxia” often prompt referral to neurology and genetics, where MRI and genetic testing help confirm how the condition is first noticed and diagnosed.
Types of Charlevoix-saguenay spastic ataxia
Charlevoix-Saguenay spastic ataxia (often shortened to ARSACS) has recognized clinical variants linked to different changes in the SACS gene. These variants can look similar overall—balance trouble, stiffness, and coordination issues—but age at onset, speed of change, and added features may differ. Symptoms don’t always look the same for everyone. When people ask about types of Charlevoix-Saguenay spastic ataxia, they’re usually referring to these clinical variants rather than completely separate diseases.
Classic early-onset
Symptoms usually begin in early childhood with unsteady walking and frequent falls. Stiff legs and coordination problems in the arms and hands gradually increase over time. Many also develop vision nerve changes and thickened nerve fibers on testing.
Juvenile-onset variant
First signs appear later in childhood or the teen years, with a slower early course than the classic type. Balance and gait difficulties still dominate, but daily tasks like handwriting or buttoning may become challenging over time. Eye movement or vision issues can emerge later.
Adult-onset variant
Symptoms start in adulthood, often with milder early balance problems and leg stiffness. Progression is typically slower, and some features seen in childhood cases may be subtler. This variant illustrates how the balance of symptoms can shift over time.
Atypical presentations
Some people primarily notice peripheral nerve symptoms like weakness or numbness in the feet and lower legs. Others may show prominent eye movement problems or speech and swallowing difficulty earlier than expected. These patterns are recognized variants of ARSACS rather than separate conditions.
Founder-region form
In people with ancestry from the Charlevoix–Saguenay regions of Québec, specific shared gene changes are common. The clinical picture is usually the classic early-onset pattern, though severity can vary from family to family. Discussing family origins can help interpret types of Charlevoix-Saguenay spastic ataxia in context.
What genetics can tell you about symptoms
Certain SACS gene variants damage nerve cells in the cerebellum and spinal cord, leading to early balance problems, leg stiffness, and clumsy, uncoordinated movements. More disruptive variants often cause earlier walking delays, vision changes like nystagmus, and gradual worsening of speech and coordination.
Causes and risk factors
Charlevoix-Saguenay spastic ataxia is caused by changes in a gene called SACS.
A child develops it when they inherit two altered copies, one from each healthy carrier parent.
Some risks are written in our DNA, passed down through families.
Risk is higher with family history, carrier parents, when parents are related, or in families from the Charlevoix–Saguenay region of Québec.
Lifestyle and environment do not cause the disease, but they may affect how early symptoms of Charlevoix-Saguenay spastic ataxia appear and how fast problems progress.
Environmental and biological risk factors
Research to date has not found environmental or pregnancy-related biological factors that change the chance of Charlevoix-saguenay spastic ataxia occurring. Doctors often group risks into internal (biological) and external (environmental). For this condition, studies have not confirmed links on either side, so the elements below emphasize areas where no association has been shown.
No specific environmental risk factors for Charlevoix-saguenay spastic ataxia have been identified in human studies. Investigations have not linked air pollution, heavy metals, radiation, or endocrine-disrupting chemicals to higher likelihood.
Advanced maternal or paternal age has not been shown to affect the chance of this condition occurring. Available data do not suggest an age-related effect.
Pregnancy conditions such as diabetes, high blood pressure, or common infections have not been associated with increased risk. Prenatal care remains important for overall pregnancy health.
Preterm birth, birth weight, or delivery method do not appear to determine whether a child has this condition. These features may influence newborn wellbeing in other ways but not its occurrence.
Genetic risk factors
Charlevoix-Saguenay spastic ataxia (ARSACS) arises from changes in a single gene and follows a recessive inheritance pattern. Some risk factors are inherited through our genes. The genetic causes of Charlevoix-Saguenay spastic ataxia center on variants in the SACS gene, which impair a nerve-cell protein called sacsin. Risk is higher when both parents carry a SACS variant or in communities with known founder changes.
SACS gene changes: ARSACS is caused by disease-causing variants in the SACS gene. These changes disrupt sacsin, a protein important for nerve cell health.
Autosomal recessive: The condition appears when someone inherits two SACS variants, one from each parent. People with a single variant (carriers) usually do not have symptoms.
Carrier parents: If both parents are carriers, each pregnancy has a 25% (1 in 4) chance of an affected child. There is also a 50% (1 in 2) chance the child will be a carrier.
Founder regions: Carrier rates are higher in Quebec’s Saguenay–Lac-Saint-Jean and Charlevoix regions due to long-standing founder variants. Similar patterns have been reported in some other communities worldwide.
Family history: Having relatives with ARSACS raises the chance of being a carrier. This can guide who might consider carrier or diagnostic testing.
Related parents: Parents who are related by blood have a higher chance of sharing the same SACS variant. This increases the likelihood of a child inheriting two variants.
Genetic testing: Testing the SACS gene can confirm a diagnosis and identify carriers in a family. It can look for both small changes and missing or extra pieces of the gene.
Lifestyle risk factors
Charlevoix-saguenay spastic ataxia is a genetic condition; lifestyle habits do not cause it. However, daily routines can meaningfully influence symptoms, mobility, and complications over time. Here’s how lifestyle affects Charlevoix-saguenay spastic ataxia and the lifestyle risk factors for Charlevoix-saguenay spastic ataxia. Tailored choices can help preserve function and safety.
Regular, supervised aerobic and strength exercise can maintain walking endurance and slow deconditioning. It may lessen spasticity and improve coordination for daily tasks.
Prolonged sitting or inactivity accelerates muscle weakness and stiffness. Short movement breaks preserve joint range and reduce spasticity-related discomfort.
Daily hamstring, calf, and hip stretches help prevent contractures that worsen gait. Night positioning programs can maintain ankle dorsiflexion for safer steps.
Task-specific balance and coordination drills reduce fall risk and improve transfers. Core strengthening and gaze-stabilization exercises may ease ataxia-related unsteadiness.
Risk prevention
Charlevoix‑Saguenay spastic ataxia is a genetic condition passed down in families, so there’s no way to prevent the condition itself once the genes are set. Prevention focuses on lowering the chance of complications, staying safe and mobile, and protecting overall health. Prevention can mean both medical steps, like vaccines, and lifestyle steps, like exercise. The steps below aim to reduce falls, infections, pain, and other preventable problems while supporting day‑to‑day function.
Meeting with a genetics professional can clarify your personal and family risk for Charlevoix‑Saguenay spastic ataxia. Carrier testing for partners and relatives can guide family planning decisions.
If both partners are carriers, options like IVF with embryo testing or prenatal testing can reduce the chance of passing on the condition. A genetic counselor can explain benefits, limits, and timing.
Ongoing visits help track balance, stiffness, and coordination changes in Charlevoix‑Saguenay spastic ataxia. Early adjustments to therapy or equipment can prevent avoidable setbacks.
A tailored program focused on balance, strength, and stretching can reduce falls and muscle tightness in Charlevoix‑Saguenay spastic ataxia. Home exercises between sessions help keep gains.
Transmission
Charlevoix-saguenay spastic ataxia is not contagious; you can’t catch it or pass it through casual contact. It is a recessive genetic condition, which means a child develops Charlevoix-saguenay spastic ataxia only when they inherit two nonworking copies of the gene—one from each parent who is a carrier. When both parents are carriers, each pregnancy has a 25% (1 in 4) chance of a child with Charlevoix-saguenay spastic ataxia, a 50% (1 in 2) chance of a carrier, and a 25% chance of neither; carriers typically have no symptoms. Genetic counseling and testing can explain the genetic transmission of Charlevoix-saguenay spastic ataxia in your family and how Charlevoix-saguenay spastic ataxia is inherited.
When to test your genes
Charlevoix‑Saguenay spastic ataxia is a genetic condition, so testing is most useful if you have neurologic symptoms (gait imbalance, muscle stiffness, speech changes) or a family history, especially in Saguenay–Lac‑Saint‑Jean ancestry. Test before pregnancy for reproductive planning, or earlier to guide supportive therapies. Discuss with a genetic counselor first.
Diagnosis
Charlevoix-Saguenay spastic ataxia is usually identified by a recognizable pattern that starts in childhood: balance problems, leg stiffness, and often changes in speech and nerve function. Doctors use clinical clues and tests to make the diagnosis of Charlevoix-Saguenay spastic ataxia. Getting a diagnosis is often a turning point toward answers and support. The final confirmation typically comes from genetic testing.
Doctors review when balance issues, frequent falls, or leg stiffness began and how they’ve changed over time. Early symptoms of Charlevoix-Saguenay spastic ataxia often appear in early childhood and slowly progress.
The exam looks for coordination problems, leg spasticity, brisk reflexes, and signs of nerve weakness in the feet and hands. These findings create a pattern that points toward a spastic ataxia.
Imaging often shows shrinkage of the cerebellum and characteristic signal patterns in brainstem pathways. These imaging findings support the clinical picture and help distinguish it from other ataxias.
Nerve conduction tests and electromyography can show peripheral neuropathy, which is common in this condition. Demonstrating nerve damage outside the brain supports the overall diagnosis.
Stages of Charlevoix-saguenay spastic ataxia
Charlevoix-saguenay spastic ataxia does not have defined progression stages. It usually begins in early childhood and slowly gets worse, but the pace and mix of issues—balance problems, leg stiffness, and nerve changes—differ a lot between people, so there isn’t a standard staging system. Early symptoms of Charlevoix-saguenay spastic ataxia like frequent falls or clumsy walking often lead to an evaluation that includes a neurological exam, a look at family history, and sometimes brain MRI. Different tests may be suggested to help confirm the diagnosis, including genetic testing for changes in the SACS gene.
Outlook and prognosis
Looking at the long-term picture can be helpful. Many people with Charlevoix-Saguenay spastic ataxia notice early symptoms in childhood—unsteady walking, frequent falls, or leg stiffness—and these usually progress slowly over years. For many, mobility declines over time, with increasing spasticity and coordination problems that make everyday tasks like climbing stairs or handwriting harder. Speech can become slurred, and some develop vision or nerve involvement in the hands and feet. The outlook is not the same for everyone, but with steady rehabilitation, assistive devices, and treatment of muscle tightness, many people maintain independence in school, work, and daily life longer than they expect.
Prognosis refers to how a condition tends to change or stabilize over time. In Charlevoix-Saguenay spastic ataxia, life expectancy is often near typical, because the condition mainly affects movement rather than vital organs. Complications usually relate to falls, swallowing difficulties, nutrition, or respiratory issues from reduced mobility, which is why proactive care—physical therapy, speech and swallow support, and fall prevention—matters. Over time, most people need more support for walking, sometimes moving from braces to a walker or wheelchair, but cognition is typically preserved, and many continue school or work with adaptations.
When thinking about the future, it helps to plan for periodic reassessment so treatments can be adjusted as needs change. With ongoing care, many people maintain meaningful routines, relationships, and goals, even as symptoms progress. Families often want to know what role they can play.. Encourage regular check-ins with neurology and rehabilitation, optimize bone health and nutrition, and address mood and sleep—small steps that can protect long-term function. Talk with your doctor about what your personal outlook might look like, including ways to lower risks tied to falls and swallowing, and revisit the plan as life circumstances evolve.
Long-term effects
Charlevoix-Saguenay spastic ataxia often changes movement, balance, and coordination over many years, which can affect school, work, and daily tasks. Long-term effects vary widely, and not everyone experiences the same pattern or pace of change. Most people notice a slow progression, with periods that feel steadier and others that bring new challenges. Regular follow-up helps tailor support as needs evolve.
Walking may become slower and stiffer over time. Many eventually need a cane, walker, or wheelchair for safety and distance.
Balance can worsen, making uneven ground, curbs, or stairs risky. Fall prevention and home adjustments can reduce injuries.
Muscles, especially in the legs, may feel tight and cramp easily. This can make standing, turning, and longer walks tiring.
Fine hand control can become clumsy, affecting writing, buttons, or tools. Tasks may take longer but can be adapted.
How is it to live with Charlevoix-saguenay spastic ataxia?
Living with Charlevoix‑Saguenay spastic ataxia often means planning your day around balance, stiffness, and fatigue, with walking aids, railings, or a wheelchair making movement safer and less draining. Fine-motor tasks like buttoning clothes or typing can take extra time, and speech may be slower or slurred, so people often pace conversations and use tools or therapy to keep communication clear. Families, friends, and coworkers usually become part of the routine—offering rides, adapting homes or workplaces, and learning how to spot when rest, stretching, or help is needed—while also sharing in problem‑solving that keeps independence and social life strong. Many find that steady physical therapy, assistive technology, and a predictable rhythm of rest and activity help maintain confidence and participation at school, work, and in the community.
Treatment and drugs
Treatment for Charlevoix–Saguenay spastic ataxia focuses on easing symptoms, protecting mobility, and supporting daily function over time. Medicines that ease symptoms are called symptomatic therapies, and may include drugs to reduce muscle stiffness and spasms, help with balance or tremor, manage nerve pain, and treat mood or sleep issues as needed. Physical therapy, occupational therapy, and speech therapy are core parts of care to maintain strength, flexibility, safe walking, hand coordination, and clear communication, and braces, walkers, or wheelchairs can improve safety and independence when balance worsens. Your doctor may suggest vitamin supplementation and routine monitoring for features like neuropathy or vision changes, and in some centers, genetic counseling is offered for family planning. Not every treatment works the same way for every person, so plans are adjusted over time to match changing needs and goals.
Non-drug treatment
Charlevoix-saguenay spastic ataxia can affect walking, hand control, and speech in everyday life. Non-drug treatments often lay the foundation for daily function and safety. Starting therapy early—even when early symptoms of Charlevoix-saguenay spastic ataxia first show up—may help preserve mobility and independence. Care plans are tailored by a team and adjusted as needs change over time.
Targeted exercises build strength, stretch tight muscles, and improve walking and balance. Therapists also coach energy-saving movement patterns and safe transfers.
Training focuses on hand coordination and everyday tasks like dressing, writing, or cooking. Adaptive tools and home adjustments can make routines easier and safer.
Techniques help with clearer speech and breath control. Swallowing assessments guide safe eating and drinking to reduce choking risk.
Daily stretches ease spasticity and help prevent contractures. Positioning strategies and gentle range-of-motion routines support joint comfort.
Your genes may have an impact on how drugs work for you
Medicines for Charlevoix‑Saguenay spastic ataxia can work differently depending on gene variants that affect how your body processes drugs or how nerve cells respond. Pharmacogenetic testing may guide dose choices or medication selection, helping reduce side effects and improve benefit.
Pharmacological treatments
There’s no single medicine that cures Charlevoix-saguenay spastic ataxia, so treatment focuses on easing day-to-day symptoms like stiffness, spasms, balance problems, pain, and bladder issues. Drugs that target symptoms directly are called symptomatic treatments. Some medicines are used when early symptoms of Charlevoix-saguenay spastic ataxia like leg stiffness and balance trouble begin to affect daily activities. Choices are tailored over time based on what helps and what side effects show up.
Helps relax tight, spastic muscles to ease walking and transfers. Common side effects include sleepiness, dizziness, or weakness.
Eases muscle tone and spasms, especially later in the day. It may cause drowsiness, dry mouth, or low blood pressure.
Lowers muscle contraction from within the muscle itself. Liver monitoring may be needed, and fatigue or weakness can occur.
Targeted injections can soften overactive muscles that pull joints out of position. Effects build over 1–2 weeks and last about 3–4 months.
Genetic influences
Charlevoix‑Saguenay spastic ataxia typically occurs when a person inherits two nonworking copies of the SACS gene—one from each parent. A “carrier” means you hold the gene change but may not show symptoms. If both parents are carriers, each pregnancy has a 25% chance of a child being affected, a 50% chance the child will be a carrier, and a 25% chance of neither change. The condition is seen more often in families with roots in Quebec’s Saguenay–Lac‑Saint‑Jean and Charlevoix regions due to a historical founder effect, but it can occur in people of any background. Severity and the age when symptoms start can vary widely, even among relatives with the same SACS changes. Genetic testing for Charlevoix‑Saguenay spastic ataxia can confirm the diagnosis, guide care, and support family planning discussions with a genetic counselor.
Is Charlevoix-saguenay spastic ataxia genetic?
Genetics is central in Charlevoix-Saguenay spastic ataxia; it’s an inherited condition caused by variants in a single gene. Most cases follow an autosomal recessive pattern, meaning two altered copies are needed. Family history and carrier status strongly influence risk.
Pharmacogenetics—how genetics influence drug effects
Because Charlevoix-saguenay spastic ataxia is genetic, care focuses on easing symptoms and avoiding medicines that could worsen balance or nerve function. Changes in the gene that causes it don’t usually change how the body breaks down most drugs, but many living with the condition are more sensitive to sedation or muscle relaxants, so doses are started low and adjusted slowly. Differences in the genes that control drug‑processing enzymes can affect response to common treatments for spasticity, nerve pain, mood, or sleep—for example, some people clear certain muscle relaxants or antidepressants faster or slower, which can shift both benefit and side effects. Alongside your medical history and current medicines, genetic testing may help your team choose safer starting doses and avoid interactions. When side effects keep appearing or a treatment brings little relief despite careful dosing, this information can point to alternatives or a different route of delivery, like topical options or targeted injections. Genes are just part of the picture, though—kidney and liver health, other prescriptions, and your day‑to‑day goals all guide decisions about medications for Charlevoix-saguenay spastic ataxia.
Interactions with other conditions
Day-to-day, infections, pain, or even poor sleep can temporarily make balance and stiffness worse in Charlevoix-Saguenay spastic ataxia. Doctors call it a “comorbidity” when two conditions occur together, and some are fairly common here, such as bladder problems that raise the risk of urinary tract infections, which can spike spasticity and fatigue. Limited mobility over time can contribute to weaker bones and falls, so osteoporosis and fractures may become part of the picture if prevention isn’t in place. Mood conditions like anxiety or depression can also occur alongside Charlevoix-Saguenay spastic ataxia, and the added stress often intensifies tremor, muscle tightness, or sleep trouble. Infections or fever may noticeably worsen early symptoms of Charlevoix-Saguenay spastic ataxia, such as walking, coordination, or leg stiffness, but these flares often settle once the trigger is treated. Some features overlap with other neurologic diseases, which can complicate diagnosis and care, and medicines used for spasticity or bladder control may interact with treatments for other conditions by causing more sedation or constipation.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described unsteady walking, stiff limbs, and slurred speech appearing in several relatives across generations. Families and communities once noticed patterns that a child who learned to walk later might, as a teen or young adult, develop a wide‑based gait and muscle tightness; grandparents sometimes recalled similar stories from their youth. These observations set the stage for what medicine now recognizes as Charlevoix‑Saguenay spastic ataxia.
First described in the medical literature as a cluster of cases in the Charlevoix and Saguenay–Lac‑Saint‑Jean regions of Quebec, the condition was initially mapped through careful family trees and long‑term follow‑up. Doctors noticed a consistent mix of balance problems (ataxia) and muscle stiffness (spasticity), often beginning in childhood or adolescence, and passed down in an autosomal recessive pattern. From these first observations, clinicians broadened their view and began identifying people with similar features outside Quebec, showing it was not limited to one place.
As medical science evolved, brain and nerve imaging, electrical studies, and standardized exams clarified which symptoms belonged to Charlevoix‑Saguenay spastic ataxia and which pointed to other disorders. Early reports emphasized walking difficulties and speech changes; later descriptions added eye movement findings, hand coordination, and the pace of progression. Not every early description was complete, yet together they built the foundation of today’s knowledge.
Advances in genetics turned clues into confirmation. Careful mapping within large families narrowed the search to a specific chromosome region, and DNA research now explains the condition at the gene level. Identifying the responsible gene allowed precise testing, carrier detection, and confident diagnosis, even when early symptoms of Charlevoix‑Saguenay spastic ataxia were subtle or overlapped with other conditions. It also helped researchers understand why some people progress more slowly than others and why supportive therapies may need to be tailored.
In recent decades, awareness has grown beyond the original communities. Clinicians in North America and Europe recognized similar patterns, and international collaborations refined diagnostic criteria and follow‑up care. Historical differences highlight why modern definitions include both what people feel—the fatigue, ankle stiffness, and balance loss—and what examiners measure—reflex changes, gait tests, and eye movements.
Knowing the condition’s history helps explain today’s approach: listen for family stories, examine carefully over time, and use genetic testing to confirm. Each step—from community observations to molecular findings—has shaped how Charlevoix‑Saguenay spastic ataxia is recognized, named, and supported in clinics today.